Enis Otuk
Harpenden
Summary
- Commercial and marketing executive with 20+ years of leadership across innovative and generic pharmaceuticals in Europe, North America, JANZ and Emerging Markets.
- As Country Manager Ireland, doubled the flagship brand EpiPen net sales and redesigned pricing architecture across 70+ Gx products, delivering >100% profit uplift.
- Selected to the executive core team leading growth acceleration and sales & marketing cost optimisation across one of the industry's broadest established brands portfolios. Built the end-to-end Tail Brands operating model. Owned global strategy for a $2.5B portfolio across 40+ markets and designed the company's first global digital-first Tail Brands model, reversing multi-year decline.
- Previously led the UK branded organisation (65+ FTE), delivered +60% growth across promoted brands, launched Europe's first scalable omnichannel model (Pf Award 2021), and drove EU-wide adoption of the Creative & Content CoE, enabling >£100M cumulative savings.
- Recognised for shaping global portfolio strategy, driving scientific consensus with international KOLs and delivering high impact commercial transformation across complex healthcare systems.
- Experienced in building and managing third-party partnerships across country and global roles, driving stronger commercial performance, improved execution, and broader omnichannel capability.
Overview
25
25
years of professional experience
Work History
Country Manager
Viatris
Ireland
03.2024 - 03.2026
- Managed full P&L and operational oversight for Irish business units within branded, generic, and OTC segments.
- Led strategic payer alignment to achieve a 50% price increase for flagship brand EpiPen, doubling net sales through promotional campaigns in two years.
- Revised pricing for Gx products contributed to a 100% profit uplift.
- Resolved persistent demand–supply issues and strengthened third-party alliance partnerships, delivering a 90% sales uplift.
Head of Global Established (Tail) Brands
Viatris
UK
02.2021 - 02.2024
- Appointed to the executive core team to accelerate growth and optimise sales and marketing spend across a broad global established brands portfolio.
- Created and led a new Global Established (Tail) Brands function focused on brand-country combinations with limited growth potential or sustained decline, using a digital-only promotional model to improve performance at lower cost.
- Built the end-to-end Tail Brands operating model, covering portfolio segmentation, strategy development, tactical planning, content generation, MLR approval, job aids, KPI definition, governance, and affiliate execution.
- Owned global strategy for a $2.5B portfolio across 40+ markets and designed the company’s first global Tail Brands model built on three strategic pillars, reversing multi-year decline.
- Developed centrally created, locally adaptable digital content and assets, enabling scale without field-force expansion and supporting significant sales and marketing cost optimisation.
- Led omnichannel enablement for Tail Brands through third-party partnerships, expanding execution scale and strengthening market support across the US and EU.
- Enabled country teams to establish successful third-party alliances for Tail Brands management across key markets.
- Delivered an EU turnaround from -5% decline in 2021 to +2% growth in 2023 across a $500M portfolio.
- Stabilised performance in North America and JANZ and accelerated double-digit growth in Emerging Markets.
Head of Marketing UK | Head of Branded Sales UK | EU Launch CoE
Mylan/Viatris
UK
07.2016 - 01.2021
- Led the UK branded organisation (65+ FTE) and delivered +60% revenue growth across promoted brands (Creon, EpiPen, Dymista, Femoston).
- Designed and launched Europe's first scalable omnichannel operating model, winning the Pf Award 2021.
- Implemented the Creative & Content CoE model 100% in the UK, becoming the first affiliate to fully transition from local agencies.
- Led EU-wide adoption of the CoE model, enabling >£100M cumulative savings across Europe.
Global Cardio-Metabolic Therapeutic Area Lead
Mylan
Switzerland
02.2015 - 07.2016
- Led a 21-KOL global scientific consensus program on atherogenic dyslipidaemia.
- Developed a landmark consensus publication and launched the program at a flagship ESC symposium.
- Enabled integrated medical–marketing activation across affiliates, shifting the EU franchise from decline to growth.
Global Product Manager & Developed Markets Cardio-Metabolic Therapeutic Area Lead
Abbott
Switzerland
06.2012 - 02.2015
- Led a global brand team for Lipanthyl (fenofibrate), overseeing a £300M annual sales franchise.
- Led the successful launch of the first pharmacological treatment for diabetic retinopathy progression.
- Received the 2015 President's Award with the first fibrate-statin global launch.
- Co-led the transformation into a patient-centric portfolio model.
Senior Product Manager
Abbott
Turkey
12.2010 - 05.2012
Group Product Manager
Solvay
Turkey
06.2009 - 12.2010
Product Manager
Solvay
Turkey
07.2005 - 06.2009
Sales Representative
Solvay
Turkey
01.2002 - 07.2005
Sales Representative
GSK
Turkey
04.2001 - 12.2001
Education
MBA -
Yeditepe University
Turkey01.2010
BSc - Chemical Engineering
Istanbul University
Turkey01.1999
Skills
- P&L ownership
- Country leadership
- Global Portfolio Strategy
- Pricing & Market Access
- Omnichannel GTM Models
- Launch Excellence (EU & EM)
- Cross-Functional Leadership
- Global KOL Management
- Brand Strategy & Forecasting
- Commercial Capability Building
- Business Growth Strategy
- International Stakeholder Engagement
- Talent Leadership
- Patient-Centric Portfolio Models
- Business development
- Strategic Partnership & Alliance Management
Hobbies and Interests
- Scuba diving
- Skiing
- Cycling
- Running
Hobbies and interests
- Skiing
- Scuba diving
- Cycling
- Running
Timeline
Country Manager
Viatris
03.2024 - 03.2026
Head of Global Established (Tail) Brands
Viatris
02.2021 - 02.2024
Head of Marketing UK | Head of Branded Sales UK | EU Launch CoE
Mylan/Viatris
07.2016 - 01.2021
Global Cardio-Metabolic Therapeutic Area Lead
Mylan
02.2015 - 07.2016
Global Product Manager & Developed Markets Cardio-Metabolic Therapeutic Area Lead
Abbott
06.2012 - 02.2015
Senior Product Manager
Abbott
12.2010 - 05.2012
Group Product Manager
Solvay
06.2009 - 12.2010
Product Manager
Solvay
07.2005 - 06.2009
Sales Representative
Solvay
01.2002 - 07.2005
Sales Representative
GSK
04.2001 - 12.2001
MBA -
Yeditepe University
BSc - Chemical Engineering
Istanbul University